Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.

Whitacre DC, Peters CJ, Sureau C, Nio K, Li F, Su L, Jones JE, Isogawa M, Sallberg M, Frelin L, Peterson DL, Milich DR.

Hum Vaccin Immunother. 2019 Dec 6:1-18. doi: 10.1080/21645515.2019.1689745. [Epub ahead of print]

PMID:
31809638
2.

Neonatal Exposure to Hepatitis C Virus Antigens in Uninfected Children Born to Infected Mothers.

Psaros Einberg A, Brenndörfer ED, Frelin L, Hallberg L, Sällberg M, Fischler B.

J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):106-111. doi: 10.1097/MPG.0000000000001755.

PMID:
28953534
3.

Lack of Association Between Interleukin 28B Polymorphism and Vertical Transmission of Hepatitis C.

Psaros Einberg A, Duberg AS, Filipovich O, Nyström J, Zhirkov A, Brenndörfer ED, Frelin L, Rukoiatkina E, Lobzin Y, Sällberg M, Fischler B, Lutckii A.

J Pediatr Gastroenterol Nutr. 2017 Dec;65(6):608-612. doi: 10.1097/MPG.0000000000001711.

PMID:
28820758
4.

Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.

Levander S, Holmström F, Frelin L, Ahlén G, Rupp D, Long G, Bartenschlager R, Sällberg M.

Gut. 2018 Aug;67(8):1525-1535. doi: 10.1136/gutjnl-2016-313579. Epub 2017 Jun 23.

5.

Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties.

Balasiddaiah A, Davanian H, Aleman S, Pasetto A, Frelin L, Sällberg M, Lohmann V, Koh S, Bertoletti A, Chen M.

J Virol. 2017 Apr 13;91(9). pii: e00010-17. doi: 10.1128/JVI.00010-17. Print 2017 May 1.

6.

Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses.

Holmström F, Chen M, Balasiddaiah A, Sällberg M, Ahlén G, Frelin L.

Sci Rep. 2016 May 4;6:24991. doi: 10.1038/srep24991.

7.

A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines.

Levander S, Sällberg M, Ahlén G, Frelin L.

Vaccine. 2016 May 27;34(25):2821-33. doi: 10.1016/j.vaccine.2016.04.030. Epub 2016 Apr 22.

8.

Methods to Evaluate Novel Hepatitis C Virus Vaccines.

Ahlén G, Frelin L.

Methods Mol Biol. 2016;1403:221-44. doi: 10.1007/978-1-4939-3387-7_11.

PMID:
27076133
9.

A targeted controlled force injection of genetic material in vivo.

Ahlén G, Frelin L, Holmström F, Smetham G, Augustyn S, Sällberg M.

Mol Ther Methods Clin Dev. 2016 Mar 30;5:16016. doi: 10.1038/mtm.2016.16. eCollection 2016.

10.

Copy Number Variants Associated with 14 Cases of Self-Injurious Behavior.

Shirley MD, Frelin L, López JS, Jedlicka A, Dziedzic A, Frank-Crawford MA, Silverman W, Hagopian L, Pevsner J.

PLoS One. 2016 Mar 2;11(3):e0149646. doi: 10.1371/journal.pone.0149646. eCollection 2016.

11.

Prospects and progress of DNA vaccines for treating hepatitis B.

Chen M, Jagya N, Bansal R, Frelin L, Sällberg M.

Expert Rev Vaccines. 2016 May;15(5):629-40. doi: 10.1586/14760584.2016.1131615. Epub 2016 Jan 28. Review.

PMID:
26652035
12.

Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo.

Bansal R, Frelin L, Brenndörfer ED, Storm G, Prakash J, Sällberg M.

PLoS One. 2015 Jun 1;10(6):e0128466. doi: 10.1371/journal.pone.0128466. eCollection 2015.

13.

Electroporation for therapeutic DNA vaccination in patients.

Sällberg M, Frelin L, Ahlén G, Sällberg-Chen M.

Med Microbiol Immunol. 2015 Feb;204(1):131-5. doi: 10.1007/s00430-014-0384-8. Epub 2014 Dec 23. Review.

PMID:
25535102
14.

Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination.

Brass A, Frelin L, Milich DR, Sällberg M, Ahlén G.

Mol Ther. 2015 Mar;23(3):578-90. doi: 10.1038/mt.2014.233. Epub 2014 Dec 10.

15.

Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination.

Ahlén G, Holmström F, Gibbs A, Alheim M, Frelin L.

Gene Ther. 2014 Aug;21(8):739-50. doi: 10.1038/gt.2014.48. Epub 2014 May 29.

16.

Containing "The Great Houdini" of viruses: combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C.

Ahlén G, Frelin L, Brenndörfer ED, Brass A, Weiland O, Chen M, Sällberg M.

Drug Resist Updat. 2013 Jul-Nov;16(3-5):60-7. doi: 10.1016/j.drup.2013.06.001. Epub 2013 Aug 2. Review.

17.

A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

Fournillier A, Frelin L, Jacquier E, Ahlén G, Brass A, Gerossier E, Holmström F, Broderick KE, Sardesai NY, Bonnefoy JY, Inchauspé G, Sällberg M.

J Infect Dis. 2013 Sep;208(6):1008-19. doi: 10.1093/infdis/jit267. Epub 2013 Jun 17.

18.

Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.

Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L, Sällberg M.

Mol Ther. 2013 Sep;21(9):1796-805. doi: 10.1038/mt.2013.119. Epub 2013 Jun 11.

19.

Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.

Shirley MD, Tang H, Gallione CJ, Baugher JD, Frelin LP, Cohen B, North PE, Marchuk DA, Comi AM, Pevsner J.

N Engl J Med. 2013 May 23;368(21):1971-9. doi: 10.1056/NEJMoa1213507. Epub 2013 May 8.

20.

Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients.

Rahbin N, Frelin L, Aleman S, Hultcrantz R, Sällberg M, Brenndörfer ED.

Biochem Biophys Res Commun. 2013 Mar 29;433(1):31-5. doi: 10.1016/j.bbrc.2013.02.075. Epub 2013 Feb 27.

PMID:
23454379
21.

A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice.

Holmström F, Pasetto A, Nähr V, Brass A, Kriegs M, Hildt E, Broderick KE, Chen M, Ahlén G, Frelin L.

J Immunol. 2013 Feb 1;190(3):1113-24. doi: 10.4049/jimmunol.1201497. Epub 2013 Jan 2.

22.

Unexpected relationships and inbreeding in HapMap phase III populations.

Stevens EL, Baugher JD, Shirley MD, Frelin LP, Pevsner J.

PLoS One. 2012;7(11):e49575. doi: 10.1371/journal.pone.0049575. Epub 2012 Nov 19.

23.

Methods for monitoring gene gun-induced HBV- and HCV-specific immune responses in mouse models.

Ahlén G, Sällberg M, Frelin L.

Methods Mol Biol. 2013;940:239-67. doi: 10.1007/978-1-62703-110-3_20.

PMID:
23104348
24.

TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity.

Pasetto A, Frelin L, Aleman S, Holmström F, Brass A, Ahlén G, Brenndörfer ED, Lohmann V, Bartenschlager R, Sällberg M, Bertoletti A, Chen M.

J Immunol. 2012 Nov 1;189(9):4510-9. doi: 10.4049/jimmunol.1201613. Epub 2012 Sep 28.

25.

Limited effect on NS3-NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease.

Ahlén G, Chen A, Roe B, Falkeborn T, Frelin L, Hall WW, Sällberg M, Söderholm J.

J Gen Virol. 2012 Aug;93(Pt 8):1680-6. doi: 10.1099/vir.0.043745-0. Epub 2012 May 16.

PMID:
22592266
26.

Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3.

Pasetto A, Frelin L, Brass A, Yasmeen A, Koh S, Lohmann V, Bartenschlager R, Magalhaes I, Maeurer M, Sällberg M, Chen M.

J Gen Virol. 2012 Feb;93(Pt 2):247-58. doi: 10.1099/vir.0.037903-0. Epub 2011 Nov 9.

27.

Identification of a unique double-negative regulatory T-cell population.

Lee BO, Jones JE, Peters CJ, Whitacre D, Frelin L, Hughes J, Kim WK, Milich DR.

Immunology. 2011 Dec;134(4):434-47. doi: 10.1111/j.1365-2567.2011.03502.x.

28.

A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies.

Malik IR, Chen A, Brass A, Ahlén G, Rahman M, Sällberg M, Qureshi JA, Frelin L.

Scand J Infect Dis. 2012 Jan;44(1):55-9. doi: 10.3109/00365548.2011.608711. Epub 2011 Sep 21.

PMID:
21933033
29.

Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production.

Brenndörfer ED, Brass A, Söderholm J, Frelin L, Aleman S, Bode JG, Sällberg M.

Gut. 2012 Apr;61(4):589-96. doi: 10.1136/gut.2010.232116. Epub 2011 Aug 3.

PMID:
21813471
30.

Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis.

Söderberg C, Marmur J, Eckes K, Glaumann H, Sällberg M, Frelin L, Rosenberg P, Stål P, Hultcrantz R.

APMIS. 2011 Jul;119(7):412-20. doi: 10.1111/j.1600-0463.2011.02746.x. Epub 2011 Apr 25.

PMID:
21635548
31.

Performance assessment of copy number microarray platforms using a spike-in experiment.

Halper-Stromberg E, Frelin L, Ruczinski I, Scharpf R, Jie C, Carvalho B, Hao H, Hetrick K, Jedlicka A, Dziedzic A, Doheny K, Scott AF, Baylin S, Pevsner J, Spencer F, Irizarry RA.

Bioinformatics. 2011 Apr 15;27(8):1052-60. doi: 10.1093/bioinformatics/btr106.

32.

Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination.

Chen A, Ahlén G, Brenndörfer ED, Brass A, Holmström F, Chen M, Söderholm J, Milich DR, Frelin L, Sällberg M.

J Immunol. 2011 May 1;186(9):5107-18. doi: 10.4049/jimmunol.1001790. Epub 2011 Mar 23.

33.

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Frelin L, Brass A, Ahlén G, Brenndörfer ED, Chen M, Sällberg M.

Drug News Perspect. 2010 Dec;23(10):647-53. doi: 10.1358/dnp.2010.23.10.1513492. Review.

PMID:
21180650
34.

Anti-tumor necrosis factor α treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C.

Brenndörfer ED, Weiland M, Frelin L, Derk E, Ahlén G, Jiao J, Bode JG, Sällberg M.

Hepatology. 2010 Nov;52(5):1553-63. doi: 10.1002/hep.23870.

PMID:
20886569
35.

Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes.

Nyström J, Chen A, Frelin L, Ahlén G, Koh S, Brass A, Peterson DL, Fons M, Milich DR, Hultgren C, Sällberg M.

J Infect Dis. 2010 Jun 15;201(12):1867-79. doi: 10.1086/652808.

PMID:
20446851
36.

The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo.

Kriegs M, Bürckstümmer T, Himmelsbach K, Bruns M, Frelin L, Ahlén G, Sällberg M, Hildt E.

J Biol Chem. 2009 Oct 9;284(41):28343-51. doi: 10.1074/jbc.M109.038877. Epub 2009 Aug 12.

37.

DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target.

Sällberg M, Frelin L, Weiland O.

Expert Opin Biol Ther. 2009 Jul;9(7):805-15. doi: 10.1517/14712590902988444. Review.

PMID:
19527105
38.

Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase.

Brenndörfer ED, Karthe J, Frelin L, Cebula P, Erhardt A, Schulte am Esch J, Hengel H, Bartenschlager R, Sällberg M, Häussinger D, Bode JG.

Hepatology. 2009 Jun;49(6):1810-20. doi: 10.1002/hep.22857.

PMID:
19475692
39.

Interaction of the hepatitis B core antigen and the innate immune system.

Lee BO, Tucker A, Frelin L, Sallberg M, Jones J, Peters C, Hughes J, Whitacre D, Darsow B, Peterson DL, Milich DR.

J Immunol. 2009 Jun 1;182(11):6670-81. doi: 10.4049/jimmunol.0803683.

40.

A small step closer to the Holy Grail of DNA vaccines: undisputed clinical benefit in humans.

Frelin L, Sällberg M.

Genome Med. 2009 Jan 23;1(1):15. doi: 10.1186/gm15.

41.

A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection.

Frelin L, Wahlström T, Tucker AE, Jones J, Hughes J, Lee BO, Billaud JN, Peters C, Whitacre D, Peterson D, Milich DR.

J Virol. 2009 Feb;83(3):1379-92. doi: 10.1128/JVI.01902-08. Epub 2008 Nov 12.

42.

Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Ahlén G, Derk E, Weiland M, Jiao J, Rahbin N, Aleman S, Peterson DL, Pokrovskaja K, Grandér D, Frelin L, Sällberg M.

Gut. 2009 Apr;58(4):560-9. doi: 10.1136/gut.2007.147264. Epub 2008 Aug 8.

43.

In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells.

Ahlén G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, Blomberg P, Fons M, Mathiesen I, Sällberg M.

J Immunol. 2007 Oct 1;179(7):4741-53.

44.

The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease.

Frelin L, Brenndörfer ED, Ahlén G, Weiland M, Hultgren C, Alheim M, Glaumann H, Rozell B, Milich DR, Bode JG, Sällberg M.

Gut. 2006 Oct;55(10):1475-83. Epub 2006 Mar 9.

45.

Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart.

Mao R, Wang X, Spitznagel EL Jr, Frelin LP, Ting JC, Ding H, Kim JW, Ruczinski I, Downey TJ, Pevsner J.

Genome Biol. 2005;6(13):R107. Epub 2005 Dec 16.

46.

In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes.

Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, Sallberg M.

J Infect Dis. 2005 Dec 15;192(12):2112-6. Epub 2005 Nov 4.

PMID:
16288375
47.

Relation between viral fitness and immune escape within the hepatitis C virus protease.

Söderholm J, Ahlén G, Kaul A, Frelin L, Alheim M, Barnfield C, Liljeström P, Weiland O, Milich DR, Bartenschlager R, Sällberg M.

Gut. 2006 Feb;55(2):266-74. Epub 2005 Aug 16.

48.

mVps24p functions in EGF receptor sorting/trafficking from the early endosome.

Yan Q, Hunt PR, Frelin L, Vida TA, Pevsner J, Bean AJ.

Exp Cell Res. 2005 Mar 10;304(1):265-73. Epub 2004 Dec 1.

PMID:
15707591
49.

Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene.

Frelin L, Ahlén G, Alheim M, Weiland O, Barnfield C, Liljeström P, Sällberg M.

Gene Ther. 2004 Mar;11(6):522-33.

PMID:
14999224
50.

Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo.

Frelin L, Alheim M, Chen A, Söderholm J, Rozell B, Barnfield C, Liljeström P, Sällberg M.

Gene Ther. 2003 Apr;10(8):686-99.

PMID:
12692597

Supplemental Content

Loading ...
Support Center